Naltrexone Treatment Centers in Alaska

Yes. Providers in Alaska must document a current OUD diagnosis to prescribe naltrexone as part of medication-assisted treatment. The intake assessment typically takes 60–90 minutes and includes a physical exam, drug screen, and psychiatric history — results are used to confirm eligibility.

Vivitrol monthly cost without insurance typically falls between $1,100 and $1,500 per injection in Alaska. The manufacturer Alkermes offers a patient-assistance co-pay savings card; state-funded programs also cover Vivitrol for uninsured patients in many counties.

Yes. Alaska Medicaid (DenaliCare) covers FDA-approved medications for opioid use disorder, including naltrexone, plus the associated counseling, drug testing, and clinic visits. Specific formulary details (preferred agents, long-acting injectables) vary by plan — check with your Alaska Medicaid (DenaliCare) managed-care organization.

Yes. Blue Cross Blue Shield plans in Alaska cover all three FDA-approved MAT medications. BCBS typically requires the provider to be in-network; most major naltrexone providers in Anchorage and across Alaska accept BCBS.

Alaska’s Good Samaritan law provides immunity from low-level drug-possession prosecution when someone seeks help for an overdose. MAT enrollment is not penalized; Alaska specifically prohibits probation or family court from forcing patients to stop naltrexone.

Typically no — Alaska family and criminal courts increasingly recognize MAT as standard medical care. Longer continuous treatment is often viewed favorably by courts as evidence of stability. Share treatment documentation with your attorney for court proceedings.

Bring a photo ID, insurance or Alaska Medicaid (DenaliCare) card (if applicable), and a list of current medications. Proof of address and pharmacy information speed up buprenorphine prescribing. Intake staff will walk you through paperwork at your first visit.

No fasting is required for routine MAT labs in Alaska. Eating a light meal before the visit is recommended to reduce nausea risk with the first medication dose. Hydration is helpful, especially for urine drug-screen collection.

Buprenorphine and methadone do not test positive on standard 5-panel drug tests — specialty panels are needed. Naltrexone and its metabolites are not screened on standard panels. Share an MAT provider letter with any employer or court drug-testing program to avoid confusion.

Yes. Most Alaska regions have perinatal-addiction programs coordinating OB care, MAT, and social support. Call 988 or SAMHSA 1-800-662-4357 for Alaska-specific referral. Anchorage-area hospitals typically have dedicated perinatal-addiction coordinators.

Not always. If your existing therapist can coordinate with your MAT prescriber, the arrangement is usually fine. Alaska MAT teams can integrate with outside therapists via signed records-release; doubling up on counseling isn’t required.

No. Your Alaska clinic cannot share any information with family members without a signed release specifying who, what information, and for how long. Patients under 18 may have parental involvement requirements — rules vary.